Infectious Diseases

Combination of chronic hepatitis С and non-alcoholic fatty liver disease

Objective. To assess the effects of concomitant non-alcoholic fatty liver disease (NAFLD) on the course of HCV infection and the efficacy of standard antiviral therapy in patients with chronic hepatitis C.
Patients and methods. This study included 168 patients with chronic hepatitis C treated in the Department of Infectious Diseases of the Military Clinical Hospital No. 5 of the National Guard of the Russian Federation. All patients received standard combination antiviral therapy, which included pegylated interferon alpha-2a at a dose of 180 μg per week and ribavirin at a dose of 800–1400 mg per day. After 6 months of treatment, we evaluated sustained virological response in patients; side effects did not affect the duration of therapy and all study participants completed their courses of treatment, although some of them required dosage reduction.
Results. Treatment was effective in two-thirds of patients (66.6%). Participants with chronic hepatitis C and NAFLD (both men and women) demonstrated more severe inflammation and hepatic fibrosis than those without NAFLD. The efficacy of standard antiviral treatment was significantly higher in chronic hepatitis C patients without NAFLD than in individuals with hepatic steatosis (85.3% vs 51.6%)
Conclusion. All patients with chronic hepatitis C should be checked for concomitant diseases before the initiation of antiviral therapy. The efficacy of antiviral therapy is significantly higher in patients without hepatic steatosis than in patients having this comorbidity.
Key words: non-alcoholic fatty liver disease, antiviral therapy, hepatic steatosis, hepatic fibrosis, chronic hepatitis C.
For citation: Patlusov E.P., Lopukhov P.D. Combination of chronic hepatitis С and non-alcoholic fatty liver disease. Infekc. bolezni (Infectious diseases). 2019; 17(2): 20–24. (In Russian).

DOI: 10.20953/1729-9225-2019-2-20-24